There are many aspects to be considered such as irAEs and super progression events in the use of anti-PD-L1/anti-PD-1 regimes as systemic immunotherapy for GC patients, but it still has been highly valued, which may improve the survival time and quality of life of patients to varying degrees. Here, CD274 is linked to gastric cancer.